Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan
International Journal of Radiation Oncology*Biology*Physics · 2024-03 · 118 (3) · 725-733
DOI: 10.1016/j.ijrobp.2023.09.047 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-03. Verfasst von Masashi Mizumoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, 305-8576, Japan. Electronic address: mizumoto@pmrc.tsukuba.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Proton Therapy, Liver Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Hokkaido University.
Abstract (Originalsprache)
PURPOSE: A prospective multicenter registry study was started May 2016 in Japan to evaluate the efficacy and safety of proton beam therapy (PBT) for hepatocellular carcinoma (HCC). METHODS AND MATERIALS: Patients who received PBT for HCC from May 2016 to June 2018 were registered in the database of the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology. Overall survival (OS), progression-free survival (PFS), and local recurrence were evaluated. RESULTS: Of the 755 registered patients, 576 with initial PBT and no duplicate cancer were evaluated. At final follow-up, 322 patients were alive and 254 had died. The median follow-up period for survivors was 39 months (0-58 months). The median OS time of the 576 patients was 48.8 months (95% CI, 42.0-55.6 months) and the 1-, 2-, 3-, and 4-year OS rates were 83.8% (95% CI, 80.5%-86.6%), 68.5% (64.5%-72.2%), 58.2% (53.9%-62.2%), and 50.1% (44.9%-55.0%), respectively. Recurrence was observed in 332 patients, including local recurrence in 45 patients. The median PFS time was 14.7 months (95% CI, 12.4-17.0 months) and the 1-, 2-, 3-, and 4-year PFS rates were 55.2% (95% CI, 51.0%-59.2%), 37.5% (33.5%-41.5%), 30.2% (26.3%-34.2%), and 22.8% (18.5%-27.4%), respectively. The 1-, 2-, 3-, and 4-year OS rates were significantly higher for tumor size 2 cm (P < .001). At final follow-up, 27 patients (4.7%) had late adverse events of grade 3 or higher, with liver failure (n = 7), and dermatitis (n = 7) being most common. CONCLUSIONS: This multicenter prospective data registry indicated that PBT for HCC gives good therapeutic effects (3-year local control rate of 90%) with a low risk of severe late adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, 305-8576, Japan. Electronic address: mizumoto@pmrc.tsukuba.ac.jp.
- Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, 462-8508, Japan.
- Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, 305-8576, Japan.
- Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, 679-5165, Japan.
- Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Fukushima, 963-8052, Japan.
- Medipolis Proton Therapy and Research Center, 4423 Higashikata, Ibusuki, Kagoshima, 891-0304, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Hokkaido University
Zitieren
APA
Mizumoto, M., Ogino, H., Okumura, T., Terashima, K., Murakami, M., Ogino, T., Tamamura, H., Akimoto, T., Waki, T., Katoh, N., Araya, M., Onoe, T., Takagi, M., Iwata, H., Numajiri, H., Okimoto, T., Uchinami, Y., Maruo, K., Shibuya, K., & Sakurai, H. (2024). Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan. International Journal of Radiation Oncology*Biology*Physics, 118(3), 725-733. https://doi.org/10.1016/j.ijrobp.2023.09.047
Vancouver
Mizumoto M, Ogino H, Okumura T, Terashima K, Murakami M, Ogino T, et al. Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan. International Journal of Radiation Oncology*Biology*Physics. 2024;118(3):725-733. doi:10.1016/j.ijrobp.2023.09.047
BibTeX
@article{Mizumoto2024,
author = {Mizumoto, Masashi and Ogino, Hiroyuki and Okumura, Toshiyuki and Terashima, Kazuki and Murakami, Masao and Ogino, Takashi and Tamamura, Hiroyasu and Akimoto, Tetsuo and Waki, Takahiro and Katoh, Norio and Araya, Masayuki and Onoe, Tsuyoshi and Takagi, Masaru and Iwata, Hiromitsu and Numajiri, Haruko and Okimoto, Tomoaki and Uchinami, Yusuke and Maruo, Kazushi and Shibuya, Kei and Sakurai, Hideyuki},
title = {Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {118},
number = {3},
pages = {725--733},
doi = {10.1016/j.ijrobp.2023.09.047}
}
EUVIMED